Insmed Incorporated (NASDAQ:INSM) is one of the best high growth healthcare stocks to buy now. Stifel raised the price target ...

In March 2026, Insmed reported positive Phase 3b ENCORE results showing ARIKAYCE added to standard multidrug therapy improved symptoms and culture conversion in patients with MAC lung disease who were ...

Insmed Inc. (NASDAQ:INSM) is one of the 10 Stocks Leaving the Market in the Dust Today. Insmed snapped a two-day losing ...

Shares of Insmed INSM gained nearly 6% on Monday after the company reported positive top-line results from the phase IIIb ...

Insmed remains a Buy, with an enterprise value near $30B and robust growth driven by Brinsupri and pipeline assets. Learn ...

Investors in Insmed Inc (Symbol: INSM) saw new options become available today, for the December 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Insmed today and set a price target of $206.00. According to TipRanks, Suvannavejh is a 5-star analyst with an average return of ...

Insmed (INSM) stock is flashing a historically bullish signal on the charts, and options may be the right way to play it ...

Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What’s driving this surge? Insmed revealed that its Phase ...

Wells Fargo analyst Tiago Fauth assigned a Buy rating to Insmed today and set a price target of $175.00. Claim 30% Off TipRanks Premium. Unlock hedge fund-level data and powerful ...

Investors in Insmed Inc (Symbol: INSM) saw new options begin trading today, for the July 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the ...